Home > Insider Trading > Filing (0001140361-14-030004)

Filing Details

Accession Number:: 0001140361-14-030004
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-07-30 19:53:46
Reporting Period:: 2014-07-28

Filing Date:: 2014-07-30
Accepted Time:: 2014-07-30 19:53:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1309702	J Paul Hastings	C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-07-28	8,385	$1.43	30,885	No	4	M	Direct
Common Stock	Disposition	2014-07-28	8,285	$21.93	22,600	No	4	S	Direct
Common Stock	Disposition	2014-07-28	100	$22.70	22,500	No	4	S	Direct
Common Stock	Acquisiton	2014-07-29	8,385	$1.43	30,885	No	4	M	Direct
Common Stock	Disposition	2014-07-29	8,385	$22.28	22,500	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-07-28	8,385	$0.00	8,385	$1.43
Common Stock	Stock Option (Right to Buy)	Disposition	2014-07-29	8,385	$0.00	8,385	$1.43

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
67,892		2017-01-11	No	4	M	Direct
59,507		2017-01-11	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	324,840	Indirect	See Footnote

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 22, 2014.
Includes 22,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
This transaction was executed in multiple trades in prices ranging from $21.60 to $22.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $21.86 to $22.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares are held by Paul J. Hastings & Steve N. De Jong, Trustors and/or TTEES, The Hastings-De Jong Lv Tr DTD May 1, 2012. The shares reported herein reflect the transfer of 1,075 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2014 from the Reporting Person to the aforementioend trust.
The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.